Aixcrypto Holdings, Inc. · NASDAQ:AIXC
Aixcrypto — Qualigen Therapeutics — Investor Presentation (February 2023)
19 slides from Aixcrypto's investor presentation, Feb 13, 2023
Slide 1: Corporate Presentation February 2023
Corporate Presentation February 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements qualigen This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materi
Slide 3: Investment Highlights
Investment Highlights qualigen THERAPEUTICS WW Driven to Deliver * Diversified life sciences company developing platform treatments for rare adult and pediatric cancers with potential for Orphan Drug Designation, while commercializing diagnostics * Oncology-focused therapeutic pipeline: * QN-302, G4
Slide 4: Pipeline and Products
Pipeline and Products qualigen Therapeutic Potential Indications | Discovery | Lead Optimization | Preclinical | IND-Enabling | Collaborator G4-Targeted Tumors QN-302 coc co, mm ETfos i sarcomas, GIST’) RAS Advanced Solid Tumors D> UNIVERSITY (KRAS G12C/G12D) of LOUISVILLE, Nucleolin-Expressing (TNB
Slide 5: 2022 Key Achievements
2022 Key Achievements qualigen THERAPEUTICS WD Driven to Deliver v In-licensed G4-selective transcription inhibitor Y Initiated exploratory toxicolo program from University College London ia my oy v Selected CRO for preclinical development v Presented three posters on efficacy and structure at 2022
Slide 6: 2023 Milestones
2023 Milestones' qualigen THERAPEUTICS WD Driven to Deliver Q1 2023 H2 2023 + Readout of additional data on in vivo Present data at major model(s) vy Orphan Drug Designation scientific conference? granted by FDA for pancreatic cancer v Initiated GLP toxicology : ae Initiate activation of first Phase
Slide 7: Qualigen licensed G4-Selective Transcription Inhibitors from UCL
* Qualigen licensed G4*-Selective Transcription Inhibitors from UCL in January 2022, including lead compound QN-302 * GAs are overrepresented in many oncogenes; their prevalence is significantly greater in cancerous vs. normal cells * QN-302 has stabilized G4 complexes, impeding transcription, repli
Slide 8: QN-302: Potential Therapeutic for Pancreatic Cancer
QN-302: Potential Therapeutic for Pancreatic Cancer qualigen THERAPEUTICS WW Driven to Deliver * Pancreatic cancer is the 4'» deadliest cancer in the US! * Five-year survival rate of only 11.5%! * 1-in-4 die within the first month after diagnosis? * Pancreatic cancer therapeutics market projected to
Slide 9: QN-302 Significantly Inhibited Tumor Growth
QN-302 Significantly Inhibited Tumor Growth e qualig Xenograft Data in MIA-PACA2 Pancreatic c Model ancer Mode * QN-302 produced tumor growth arrest and tumor regression in vivo MIA-PACA2 model Vehicle control B/W* Ss 3 3 * Compound and dosing schedule was well-tolerated, . no sign of adverse effect
Slide 10: QN-302: Proposed Phase 1a Clinical Study
QN-302: Proposed Phase 1a Clinical Study Primary Objective: Safety, Tolerability, Recommended Phase 2 Dose (RP2D) Study Design: Open-label, multicenter, dose- escalation and expansion, safety, pharmacodynamics, pharmacokinetics Dosing: Single agent, intravenously at four dose levels (3+3 design) Pha
Slide 11: RAS: Key Driver for Advanced Solid Tumors
RAS is the most common cancer oncogene, present in about 25% of all cancers ¢ Activates mutations in one of the three human RAS gene isoforms (KRAS, HRAS or NRAS) * Acts asa “hub” that activates multiple effectors; blocking any single pathway can be ineffective * RAS-targeted small molecule compound
Slide 12: RAS compound xenograft data
qualig H441 Xenograft 2 £ 1200 E iC ° ec = 1000 o = E800 x : o Dose regimen: 0) Dose regimen = 600 20 mg/kg ip = (Compound 2): Oo q2d, 21 days ro] 1 mg/kg ip q2d, & 400 g 28 days S 200 5 : E iE 0 —1— Ee Control Compound 1 Lung cancer cell line with KRAS-G12V KPC cells = RAS*/p53* murine cell line fr
Slide 13: QN-247: Selectively Targeting Cancer Cells
* QN-247 is an oligonucleotide-GNP* conjugate drug candidate with potential to treat heterogeneous cancer types * QN-247 has been shown to selectively bind to nucleolin present on surface of tumor cells, promoting cell death * Potential indications include high nucleolin-expressing malignancies, par
Slide 14: FastPack Diagnostic System
FastPack® Diagnostic System qualigen THERAPEUTICS WW Driven to Deliver Proprietary blood-based diagnostics platform developed by Qualigen and launched in 2001 Rapid and highly accurate immunoassay testing system with FastPack® Analyzer placed in over 1,000 physician offices worldwide Over $127 milli
Slide 15: FastPack Diagnostic Platform
FastPack® Diagnostic Platform Y Quick turnaround time in minutes v Highly accurate results obtained during physician office visit can enable real time adjustment of treatment Vv Relatively low ancillary overhead costs (regarding access and management of lab results) v Lower maintenance costs versus
Slide 16: NanoSynex Investment
NanoSynex Investment qualigen THERAPEUTICS WW Driven to Deliver * In May 2022, Qualigen acquired a majority stake in Israel-based NanoSynex * NanoSynex mission is to save lives by fighting antibiotic resistant bacteria using a rapid personalized antimicrobial susceptibility test (AST) * NanoSynex ai
Slide 17: Summary
e qualig * Diversified life sciences company developing platform treatments for rare adult and pediatric cancers with potential for Orphan Drug Designation, while commercializing diagnostics * Oncology-focused therapeutic pipeline: * QN-302, G4-selective transcription inhibitor for potential treatme
Slide 18: Leadership Team
Leadership Team Michael S. Poirier Chief Executive Officer, Chairman Founded Qualigen in 1996 Previous operations, marketing and commercialization in key roles at Abbott, Sanofi Pasteur and Ashirus Technologies Officer in the United States Navy, assigned to the US Atlantic Fleet Christopher Lotz VP,
Slide 19: February 2023
February 2023
Qualigen Therapeutics — Investor Presentation (February 2023) on 6ix